Profile banner
Debojyoty Bandyopadhyay

Debojyoty Bandyopadhyay

Molecular microbiologist and protein biologist, postdoctoral researcher

Liège, Belgium
uliege+1
Joined March 2026
Favicon imageorcid.org
Favicon imageinbios.uliege.be

Network

1.9K connections
🧬
Biotech Research Leaders
🦠
Microbial Pathogenesis Experts
🇨🇦
North American University Professors
🇪🇺
European Research Institutes
🇮🇳
Indian Biotech Academia
👥
Biotech HR Talent

Summary

Active experimental researcher in molecular microbiology and protein biology with hands-on expertise in microbial culture, molecular techniques, and cell culture. orcid+2
Contributed to translational and disease-focused research spanning bacterial pathogenesis and cancer biology, as evidenced by publications on UPEC multidrug resistance and lncRNA-driven hepatocellular carcinoma. nih+2
Has international postdoctoral experience and academic engagement, including affiliation with Saint Louis University and a postdoctoral role and seminar activity at Université de Liège (CIP/InBioS). nih+2
Experience spans academia and industry-facing roles (research scholar and molecular biologist roles in Kolkata; business development position at BCIL), indicating a mix of research and applied/managerial experience. stmkolkata+1

Work

Education

Projects

Writing

Increased expression of long non-coding RNA FIRRE promotes hepatocellular carcinoma by HuR-CyclinD1 axis signaling

January 1, 2024

Study showing FIRRE lncRNA is upregulated in HCC and promotes tumor growth via interaction with HuR and regulation of cyclin D1; includes mechanistic and in vivo xenograft data.

Favicon imagepmc.ncbi.nlm.nih.gov

Momordicine-I suppresses head and neck cancer growth by modulating key metabolic pathways

January 1, 2024

Study of momordicine-I (a bitter melon compound) showing inhibition of glycolysis and lipogenesis, induction of autophagy, and reduced tumor growth in head and neck cancer models.

Favicon imagepmc.ncbi.nlm.nih.gov

Combination of bactericidal antibiotics and inhibitors of Universal stress protein A (UspA): a potential therapeutic alternative against multidrug resistant Escherichia coli in urinary tract infections

January 1, 2021

Study validating small-molecule inhibitors of bacterial UspA that reduce MICs of bactericidal antibiotics against MDR-UPEC and perturb UspA levels, suggesting potential adjunct therapeutics.

Favicon imagepubmed.ncbi.nlm.nih.gov

Uropathogenic Escherichia coli in India-an Overview on Recent Research Advancements and Trends

January 1, 2021

Review summarizing recent research on UPEC in India, including resistance trends, virulence factors, and potential alternative therapeutics; co-authored contributions include analysis relevant to UPEC research.

Favicon imagepubmed.ncbi.nlm.nih.gov

Reactive oxygen species and uspA overexpession: an alternative bacterial response toward selection and maintenance of multidrug resistance in clinical isolates of uropathogenic E. coli

January 1, 2020

Investigation of ROS production and universal stress protein A (uspA) overexpression in multidrug-resistant UPEC clinical isolates and their response to sub-inhibitory bactericidal antibiotics.

Favicon imagepubmed.ncbi.nlm.nih.gov